Paysign, Inc. (NASDAQ:PAYS – Get Free Report) CEO Mark Newcomer sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $15.34, for a total value of $767,000.00. Following the sale, the chief executive officer directly owned 9,113,002 shares of the company’s stock, valued at approximately $139,793,450.68. This represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Mark Newcomer also recently made the following trade(s):
- On Thursday, August 6th, Mark Newcomer sold 150,000 shares of Paysign stock. The shares were sold at an average price of $11.88, for a total transaction of $1,782,000.00.
- On Wednesday, July 29th, Mark Newcomer sold 50,000 shares of Paysign stock. The shares were sold at an average price of $9.38, for a total transaction of $469,000.00.
Paysign Stock Performance
Paysign stock traded down $0.32 during trading hours on Wednesday, reaching $15.16. 824,590 shares of the stock were exchanged, compared to its average volume of 855,648. The stock has a market cap of $855.93 million, a P/E ratio of 59.54 and a beta of 0.83. Paysign, Inc. has a 52-week low of $3.08 and a 52-week high of $15.62. The firm’s 50 day moving average is $13.34 and its 200 day moving average is $9.37.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in PAYS. BlackRock Inc. acquired a new stake in Paysign in the second quarter valued at $25,219,000. Punch & Associates Investment Management Inc. acquired a new position in shares of Paysign during the 2nd quarter worth $16,983,000. Renaissance Technologies LLC raised its stake in shares of Paysign by 17.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,531,072 shares of the company’s stock worth $9,033,000 after buying an additional 227,300 shares during the last quarter. AWM Investment Company Inc. acquired a new position in shares of Paysign during the 2nd quarter worth $6,560,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Paysign by 16.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 575,619 shares of the company’s stock worth $3,396,000 after buying an additional 82,736 shares in the last quarter. 25.89% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the company. Lake Street Capital raised their price target on Paysign from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Weiss Ratings raised Paysign from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. Wall Street Zen cut Paysign from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 16th. DA Davidson raised their target price on Paysign from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, September 30th. Finally, Barrington Research set a $15.00 target price on Paysign in a report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $15.00.
Get Our Latest Report on Paysign
Paysign Company Profile
Paysign, Inc (NASDAQ: PAYS) provides prepaid payment and financial technology solutions, with a focus on healthcare, pharmaceutical and other specialized markets. Its platform supports the issuance and management of prepaid cards, digital payments, account services and related payment-processing activities.
The company’s healthcare offerings include patient assistance and copay programs that help pharmaceutical manufacturers distribute financial support to eligible patients. Paysign also provides payment and card solutions for plasma collection centers, including programs used to compensate plasma donors.
Featured Stories
- Five stocks we like better than Paysign
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.
